Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

Germline variants in cancer susceptibility genes among patients with mucosal melanoma.

NPJ genomic medicine·2026
Same author

A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation.

Journal of neuro-oncology·2026
Same author

Implementation of a Prospective, Multi-Center Clinical Study of Dynamic Contrast Fluorescence Imaging to Diagnose Necrotizing Soft-Tissue Infection - Challenges and Lessons Learned.

Proceedings of SPIE--the International Society for Optical Engineering·2026
Same author

DNA/RNA-Based Next-Generation Sequencing Improves the Early Diagnosis and Management of Neoplastic Bile Duct Strictures: A 6-Year, Prospective, Multi-Institutional, Real-Time Study.

Gastroenterology·2026
Same author

Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
Same journal

The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Immunotherapy in Sarcoma: Future Horizons.

Melissa Burgess1,2, Vikram Gorantla3, Kurt Weiss4,5

  • 1Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. burgessma@upmc.edu.

Current Oncology Reports
|October 2, 2015
PubMed
Summary
This summary is machine-generated.

Immunotherapy for sarcomas has evolved significantly, with adoptive T cell therapy and immune checkpoint inhibitors showing promise. Further research is needed to optimize patient selection and combination strategies for these cancer types.

Keywords:
Immune checkpoint blockadeImmunosurveillanceImmunotherapyProgrammed death-1 (PD-1)Soft tissue sarcomaTumor-infiltrating lymphocyte (TIL)

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K

Related Experiment Videos

Last Updated: Apr 1, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immunologic approaches to cancer treatment have a long history, evolving from early methods like Coley's toxin to modern strategies targeting immune regulation.
  • Sarcomas were among the first tumor types investigated for immunotherapeutic interventions.
  • Recent successes with immune checkpoint blockade in melanoma and renal cell carcinoma, and even in less immunogenic tumors, provide a strong rationale for exploring these therapies in sarcoma.

Purpose of the Study:

  • To review the historical and current landscape of immunotherapeutic strategies for sarcomas.
  • To highlight the potential of adoptive T cell therapy, particularly in synovial sarcoma expressing NY-ESO-1.
  • To discuss the rationale and potential of immune checkpoint inhibitors for sarcoma treatment.

Main Methods:

  • Review of historical immunotherapeutic interventions for sarcomas.
  • Analysis of recent clinical data on adoptive T cell therapy in synovial sarcoma.
  • Evaluation of immune checkpoint blockade efficacy in other cancers to inform sarcoma applications.

Main Results:

  • Adoptive T cell therapy has shown promise in small cohorts of synovial sarcoma.
  • Immune checkpoint blockade has demonstrated significant efficacy and durable responses in metastatic melanoma and renal cell carcinoma.
  • Emerging data suggest potential benefits of immunotherapy in traditionally "non-immunogenic" tumors, including lung and bladder cancers.

Conclusions:

  • Immunotherapy, including adoptive T cell therapy and immune checkpoint inhibitors, offers a promising avenue for sarcoma treatment.
  • Further research is crucial to identify optimal patient selection criteria for clinical trials.
  • Investigating novel combinatorial immunotherapeutic strategies is essential for improving outcomes in sarcoma patients.